US2004162308A1PendingUtilityA1

Use of methylnaltrexone and related compounds for treatment of constipation caused by endogenous opioids

57
Priority: Nov 3, 1997Filed: Feb 12, 2004Published: Aug 19, 2004
Est. expiryNov 3, 2017(expired)· nominal 20-yr term from priority
Inventors:Joseph FossMichael F. RoizenJonathan MossChun-Sun YuanWilliam Drell
A61P 1/00A61K 31/485
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of for preventing or treating gastrointestinal dysfunction and constipation caused by endogenous opioids in a patient who has been chronically taking opioids. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone most preferably by parenteral, intramuscular, intravenous or oral route.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for treating a patient with a gastrointestinal dysfunction caused by endogenous opioids, comprising administering to the patient an amount of a quaternary derivative of noroxymorphone effective to treat the gastrointestinal dysfunction.  
     
     
         2 . The method of  claim 1 , wherein the administration is parenteral.  
     
     
         3 . The method of  claim 1 , wherein the administration is intravenous.  
     
     
         4 . The method of  claim 1 , wherein the administration is intravenous and the amount is between 0.03 and 1.0 mg/kg.  
     
     
         5 . The method of  claim 1 , wherein the administration is intramuscular and the amount is between 0.03 and 1.0 mg/kg.  
     
     
         6 . The method of  claim 1 , wherein the administration is oral.  
     
     
         7 . The method of claims  1 - 6 , wherein the quaternary derivative or noroxymorphone is methylnaltrexone.  
     
     
         8 . A method for preventing in a patient a gastrointestinal dysfunction caused by endogenous opioids, comprising administering to the patient an amount of a quaternary derivative of noroxymorphone effective to treat the gastrointestinal dysfunction.  
     
     
         9 . The method of  claim 8 , wherein-the administration is parenteral.  
     
     
         10 . The method of  claim 8 , wherein the administration is intravenous.  
     
     
         11 . The method of  claim 8 , wherein the administration is intravenous and the amount is between 0.03 and 1.0 mg/kg.  
     
     
         12 . The method of  claim 1 , wherein the administration is intramuscular and the amount is between 0.03 and 1.0 mg/kg.  
     
     
         13 . The method of  claim 1 , wherein the administration is oral.  
     
     
         14 . The method of claims  8 - 13 , wherein the quaternary derivative or noroxymorphone is methylnaltrexone.  
     
     
         15 . A method for treating a patient with constipation caused by endogenous opioids, comprising administering to the patient an amount of a quaternary derivative of noroxymorphone effective to treat the constipation.  
     
     
         16 . The method of  claim 15 , wherein the administration is parenteral.  
     
     
         17 . The method of  claim 15 , wherein the administration is intravenous.  
     
     
         18 . The method of  claim 15 , wherein the administration is intravenous. and the amount is between 0.03 and 1.0 mg/kg.  
     
     
         19 . The method of  claim 15 , wherein the administration is intramuscular and the amount is between 0.03 and 1.0 mg/kg.  
     
     
         20 . The method of  claim 15 , wherein the administration is oral.  
     
     
         21 . The method of claims  15 - 20 , wherein the quaternary derivative or noroxymorphone is methylnaltrexone.  
     
     
         22 . A method for preventing in a patient constipation caused by endogenous opioids, comprising administering to the patient an amount of a quaternary derivative of noroxymorphone effective to treat the constipation.  
     
     
         23 . The method of  claim 22 , wherein the administration is parenteral.  
     
     
         24 . The method of  claim 22 , wherein the administration is intravenous.  
     
     
         25 . The method of  claim 22 , wherein the administration is intravenous and the amount is between 0.03 and 1.0 mg/kg.  
     
     
         26 . The method of  claim 22 , wherein the administration is intramuscular and the amount is between 0.03 and 1.0 mg/kg.  
     
     
         27 . The method of  claim 22 , wherein the administration is oral.  
     
     
         28 . The method of claims  22 - 28 , wherein the quaternary derivative or noroxymorphone is methylnaltrexone.

Join the waitlist — get patent alerts

Track US2004162308A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.